NCT02029430View on ClinicalTrials.gov

A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma

PHASE2CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

April 3, 2014

Primary Completion Date

April 25, 2016

Study Completion Date

April 25, 2016

Conditions

Kaposi's SarcomaHIV PositiveAIDS

Interventions

DRUG

50 mg/m2 aldoxorubicin

DRUG

100 mg/m2 aldoxorubicin

DRUG

150 mg/m2 aldoxorubicin

Trial Locations (1)

70112

Louisiana State University Health Science Center, New Orleans

Sponsors

Lead Sponsor

ImmunityBio, Inc.

All Listed Sponsors

lead

ImmunityBio, Inc.

INDUSTRY